PTC725 is a potent, selective, and orally bioavailable inhibitor of HCV NS4B, inhibits HCV 1b (Con1) replicons with EC50 of 1.7 nM.
PTC725 displays a selectivity index of >5,000 with respect to cellular GAPDH, and >1,000-fold selectivity window with respect to cytotoxicity.
PTC725 retains fully activity against HCV replicon mutants that are resistant to inhibitors of NS3 protease and NS5B polymerase, demonstrates synergistic affect in combination with alpha interferon in vivo.
